7 research outputs found
Concert recording 2018-04-22a
[Track 1]. Basta / Folke Rabe -- [Track 2]. Concerto for trombone and orchestra. I. Moderato assai ma molto maestoso [Track 3]. II. Quasi una Leggenda: Andante grave [Track 4]. III. Finale: maestoso - rondo / Launy Grondahl -- [Track 5]. Ballade / Eugene Bozza -- [Track 6]. Variations. I. Theme [Track 7]. II. Var. I [Track 8]. III. Var. II [Track 9]. IV. Var. III [Track 10]. V. Var. IV / Leon Stekke -- [Track 11].Concerto for alto trombone. II. Allegro assai / Georg Christoph Wagenseil -- [Track 12]. The days of wine and roses / Henry Mancini -- [Track 13]. Lush life / Billy Strayhorn
Concert recording 2015-04-27
[Track 01]. Blue caprice / Victor Morosco -- [Track 02]. Concerto for Stan Getz. Con fuoco ; [Track 03]. Elegy ; [Track 04]. Con brio / Richard Rodney Bennett -- [Track 05]. Sonata for alto sax and piano. I ; [Track 06]. Slowly ; Medium fast ; Freely - fast / Phil Woods
Concert recording 2013-02-01
[Track 01]. Soon ah\u27 will be done / arranged by William Dawson -- [Track 02]. Twenty-four negro melodies, op. 59. Wade in the water / Samuel Coleridge-Taylor -- [Track 03]. Multiple voices of an expanding distance / Jeffrey Mumford -- [Track 04]. On music. Invitation ; The final prelude / Shawn E. Okpcbholo -- [Track 05]. Psalm for the living / William Grant Still -- [Track 06]. Warm valley / Edward K. Duke Ellington -- [Track 07]. Betelehemu / arranged by Wendell Whalum
Concert recording 2018-05-14
[Track 1]. Impresiones de la Puna / Alberto E. Ginastera -- [Track 2]. Sextet for piano and woodwind quintet FP 100 / Francis Poulenc -- [Track 3]. Cantata. Solitudine Avvenne / Alessandro Scarlatti -- [Track 4]. Suite for flute and jazz piano trio / Claude Bolling
Association between dietary intake and function in amyotrophic lateral sclerosis
IMPORTANCE There is growing interest in the role of nutrition in the pathogenesis and progression of amyotrophic lateral sclerosis (ALS). OBJECTIVE To evaluate the associations between nutrients, individually and in groups, and ALS function and respiratory function at diagnosis. DESIGN, SETTING, AND PARTICIPANTS A cross-sectional baseline analysis of the Amyotrophic Lateral Sclerosis Multicenter Cohort Study of Oxidative Stress study was conducted from March 14, 2008, to February 27, 2013, at 16 ALS clinics throughout the United States among 302 patients with ALS symptom duration of 18 months or less. EXPOSURES Nutrient intake, measured using a modified Block Food Frequency Questionnaire (FFQ). MAIN OUTCOMES AND MEASURES Amyotrophic lateral sclerosis function, measured using the ALS Functional Rating Scale-Revised (ALSFRS-R), and respiratory function, measured using percentage of predicted forced vital capacity (FVC). RESULTS Baseline data were available on 302 patients with ALS (median age, 63.2 years [interquartile range, 55.5-68.0 years]; 178 men and 124 women). Regression analysis of nutrients found that higher intakes of antioxidants and carotenes from vegetables were associated with higher ALSFRS-R scores or percentage FVC. Empirically weighted indices using the weighted quantile sum regression method of "good" micronutrients and "good" food groups were positively associated with ALSFRS-R scores (β [SE], 2.7 [0.69] and 2.9 [0.9], respectively) and percentage FVC (β [SE], 12.1 [2.8] and 11.5 [3.4], respectively) (all P < .001). Positive and significant associations with ALSFRS-R scores (β [SE], 1.5 [0.61]; P = .02) and percentage FVC (β [SE], 5.2 [2.2]; P = .02) for selected vitamins were found in exploratory analyses. CONCLUSIONS AND RELEVANCE Antioxidants, carotenes, fruits, and vegetableswere associated with higher ALS function at baseline by regression of nutrient indices and weighted quantile sum regression analysis.We also demonstrated the usefulness of the weighted quantile sum regression method in the evaluation of diet. Those responsible for nutritional care of the patient with ALS should consider promoting fruit and vegetable intake since they are high in antioxidants and carotenes
Recommended from our members
Bronchopulmonary Dysplasia and Perinatal Characteristics Predict 1-Year Respiratory Outcomes in Newborns Born at Extremely Low Gestational Age: A Prospective Cohort Study
OBJECTIVE:To assess the utility of clinical predictors of persistent respiratory morbidity in extremely low gestational age newborns (ELGANs). STUDY DESIGN:We enrolled ELGANs (<29 weeks' gestation) at ≤7 postnatal days and collected antenatal and neonatal clinical data through 36 weeks' postmenstrual age. We surveyed caregivers at 3, 6, 9, and 12 months' corrected age to identify postdischarge respiratory morbidity, defined as hospitalization, home support (oxygen, tracheostomy, ventilation), medications, or symptoms (cough/wheeze). Infants were classified as having postprematurity respiratory disease (PRD, the primary study outcome) if respiratory morbidity persisted over ≥2 questionnaires. Infants were classified with severe respiratory morbidity if there were multiple hospitalizations, exposure to systemic steroids or pulmonary vasodilators, home oxygen after 3 months or mechanical ventilation, or symptoms despite inhaled corticosteroids. Mixed-effects models generated with data available at 1 day (perinatal) and 36 weeks' postmenstrual age were assessed for predictive accuracy. RESULTS:Of 724 infants (918 ± 234 g, 26.7 ± 1.4 weeks' gestational age) classified for the primary outcome, 68.6% had PRD; 245 of 704 (34.8%) were classified as severe. Male sex, intrauterine growth restriction, maternal smoking, race/ethnicity, intubation at birth, and public insurance were retained in perinatal and 36-week models for both PRD and respiratory morbidity severity. The perinatal model accurately predicted PRD (c-statistic 0.858). Neither the 36-week model nor the addition of bronchopulmonary dysplasia to the perinatal model improved accuracy (0.856, 0.860); c-statistic for BPD alone was 0.907. CONCLUSION:Both bronchopulmonary dysplasia and perinatal clinical data accurately identify ELGANs at risk for persistent and severe respiratory morbidity at 1 year. TRIAL REGISTRATION:ClinicalTrials.gov: NCT01435187
Recommended from our members
Respiratory Medications in Infants <29 Weeks during the First Year Postdischarge: The Prematurity and Respiratory Outcomes Program (PROP) Consortium
ObjectiveTo determine patterns of respiratory medications used in neonatal intensive care unit graduates.Study designThe Prematurity Respiratory Outcomes Program enrolled 835 babies <29 weeks of gestation in the first week. Of 751 survivors, 738 (98%) completed at least 1, and 85% completed all 4, postdischarge medication usage in-person/telephone parental questionnaires requested at 3, 6, 9, and 12 months of corrected age. Respiratory drug usage over the first year of life after in neonatal intensive care unit discharge was analyzed.ResultsDuring any given quarter, 66%-75% of the babies received no respiratory medication and 45% of the infants received no respiratory drug over the first year. The most common postdischarge medication was the inhaled bronchodilator albuterol; its use increased significantly from 13% to 31%. Diuretic usage decreased significantly from 11% to 2% over the first year. Systemic steroids (prednisone, most commonly) were used in approximately 5% of subjects in any one quarter. Inhaled steroids significantly increased over the first year from 9% to 14% at 12 months. Drug exposure changed significantly based on gestational age with 72% of babies born at 23-24 weeks receiving at least 1 respiratory medication but only 40% of babies born at 28 weeks. Overall, at some time in the first year, 55% of infants received at least 1 drug including an inhaled bronchodilator (45%), an inhaled steroid (22%), a systemic steroid (15%), or diuretic (12%).ConclusionMany babies born at <29 weeks have no respiratory medication exposure postdischarge during the first year of life. Inhaled medications, including bronchodilators and steroids, increase over the first year